XBIO Stock Overview
A biopharmaceutical company, focuses on advancing immune-oncology technologies for hard to treat cancers. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Xenetic Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.11 |
| 52 Week High | US$5.20 |
| 52 Week Low | US$2.78 |
| Beta | 2.26 |
| 11 Month Change | 8.17% |
| 3 Month Change | -1.02% |
| 1 Year Change | 34.59% |
| 33 Year Change | -71.79% |
| 5 Year Change | -66.63% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Most Shareholders Will Probably Find That The Compensation For Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Is Reasonable
Dec 15
Why We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At All
Dec 01Xenetic Biosciences reports Q2 results
Aug 12Xenetic Biosciences, VolitionRx collaborate to develop cell therapies to treat cancer
Aug 02Xenetic inks clinical manufacturing contract with Catalent
Jul 07Xenetic Biosciences reports Q3 results
Nov 13Shareholder Returns
| XBIO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 11.2% | 2.5% | 2.2% |
| 1Y | 34.6% | 16.1% | 31.6% |
Return vs Industry: XBIO exceeded the US Biotechs industry which returned 16.1% over the past year.
Return vs Market: XBIO exceeded the US Market which returned 31.6% over the past year.
Price Volatility
| XBIO volatility | |
|---|---|
| XBIO Average Weekly Movement | 11.3% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: XBIO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: XBIO's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 4 | Jim Parslow | www.xeneticbio.com |
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies for hard to treat cancers. The company’s proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments that targets pancreatic cancer comprising pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors.
Xenetic Biosciences, Inc. Fundamentals Summary
| XBIO fundamental statistics | |
|---|---|
| Market cap | US$6.33m |
| Earnings (TTM) | -US$4.08m |
| Revenue (TTM) | US$2.52m |
2.5x
P/S Ratio-1.6x
P/E RatioIs XBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XBIO income statement (TTM) | |
|---|---|
| Revenue | US$2.52m |
| Cost of Revenue | US$0 |
| Gross Profit | US$2.52m |
| Other Expenses | US$6.60m |
| Earnings | -US$4.08m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.64 |
| Gross Margin | 100.00% |
| Net Profit Margin | -161.58% |
| Debt/Equity Ratio | 0% |
How did XBIO perform over the long term?
See historical performance and comparison